Stock RNA AVIDITY BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
27.94 USD +0.87% Intraday chart for Avidity Biosciences, Inc. +5.00% +208.73%
Jun. 05 Avidity Biosciences Insider Sold Shares Worth $767,780, According to a Recent SEC Filing MT
May. 17 Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Avidity Biosciences Insider Sold Shares Worth $767,780, According to a Recent SEC Filing
Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing
Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors
Avidity Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing
Avidity Biosciences Insider Sold Shares Worth $609,017, According to a Recent SEC Filing
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing
Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor? Trial
Apprehension About Key Inflation Data Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday
Avidity Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Avidity Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Avidity Biosciences Receives US FDA's Rare Pediatric Disease Designation for AOC 1044 in Duchenne Muscular Dystrophy
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences Appoints Strategy Chief, Plans to Start Phase 3 Myotonic Dystrophy Type 1 Study
Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024
Avidity Biosciences, Inc. Announces Resignation of Eric Mosbrooker as Board of Directors and the Human Capital Management Committee of the Board
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNA Stock
  4. News Avidity Biosciences, Inc.
  5. Other languages